NO975665D0 - Farmasöytisk sammensetning inneholdende en proteinaseinhibitor og et monoglyserid - Google Patents

Farmasöytisk sammensetning inneholdende en proteinaseinhibitor og et monoglyserid

Info

Publication number
NO975665D0
NO975665D0 NO975665A NO975665A NO975665D0 NO 975665 D0 NO975665 D0 NO 975665D0 NO 975665 A NO975665 A NO 975665A NO 975665 A NO975665 A NO 975665A NO 975665 D0 NO975665 D0 NO 975665D0
Authority
NO
Norway
Prior art keywords
monoglyceride
pharmaceutical composition
composition containing
proteinase inhibitor
compositions
Prior art date
Application number
NO975665A
Other languages
English (en)
Other versions
NO975665L (no
NO324531B1 (no
Inventor
Carole Anne Bailey
Josephine Christine Ferdinando
Navnit Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/616,233 external-priority patent/US6008228A/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO975665D0 publication Critical patent/NO975665D0/no
Publication of NO975665L publication Critical patent/NO975665L/no
Publication of NO324531B1 publication Critical patent/NO324531B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO19975665A 1995-06-06 1997-12-05 Enhetsdose av sammensetning omfattende en proteinaseinhibitor som er N-tert-butyl-dekahydro-2-[2(R)-hydroksy-4-fenyl-3(S)-[[N-(2-kinolylkarbonyl)-L-asparaginyl]amino]butyl]-(4aS, 8aS)-isokinolin-3(S)-karboksamid og et monoglyserid. NO324531B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46849395A 1995-06-06 1995-06-06
US08/616,233 US6008228A (en) 1995-06-06 1996-05-07 Pharmaceutical compositions containing proteinase inhibitors
PCT/EP1996/002431 WO1996039142A1 (en) 1995-06-06 1996-06-04 Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride

Publications (3)

Publication Number Publication Date
NO975665D0 true NO975665D0 (no) 1997-12-05
NO975665L NO975665L (no) 1998-02-05
NO324531B1 NO324531B1 (no) 2007-11-12

Family

ID=27042422

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975665A NO324531B1 (no) 1995-06-06 1997-12-05 Enhetsdose av sammensetning omfattende en proteinaseinhibitor som er N-tert-butyl-dekahydro-2-[2(R)-hydroksy-4-fenyl-3(S)-[[N-(2-kinolylkarbonyl)-L-asparaginyl]amino]butyl]-(4aS, 8aS)-isokinolin-3(S)-karboksamid og et monoglyserid.

Country Status (27)

Country Link
EP (1) EP0831826B1 (no)
JP (1) JP3238412B2 (no)
CN (1) CN1092960C (no)
AT (1) ATE226075T1 (no)
AU (1) AU709796B2 (no)
BG (1) BG63711B1 (no)
BR (1) BR9610842A (no)
CA (1) CA2224125C (no)
CY (1) CY2373B1 (no)
CZ (1) CZ292192B6 (no)
DE (1) DE69624354T2 (no)
DK (1) DK0831826T3 (no)
EA (1) EA001413B1 (no)
ES (1) ES2182996T3 (no)
HK (1) HK1010136A1 (no)
HU (1) HU223899B1 (no)
IL (1) IL122353A0 (no)
IS (1) IS2661B (no)
MX (1) MX9709193A (no)
NO (1) NO324531B1 (no)
NZ (1) NZ311646A (no)
OA (1) OA10546A (no)
PL (1) PL184820B1 (no)
PT (1) PT831826E (no)
SK (1) SK282121B6 (no)
TR (1) TR199701541T1 (no)
WO (1) WO1996039142A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69808463T2 (de) 1997-07-29 2003-06-26 Pharmacia & Upjohn Co., Kalamazoo Selbstemulgierende formulierung enthaltend saure lipophile verbindungen
ATE215370T1 (de) * 1997-07-29 2002-04-15 Upjohn Co Selbstemulgierende formulierung enthaltend lipophile verbindungen
PT1666026E (pt) * 1999-02-08 2012-03-15 Intarcia Therapeutics Inc Veículos viscosos não aquosos biocompatíveis monofásicos e métodos para a preparação dos mesmos
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
BR0202252A (pt) 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP2108705A1 (en) 2008-04-08 2009-10-14 Universität Duisburg-Essen Method for analysing the epigenetic status of the HtrA 1 gene in a biological sample
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor

Also Published As

Publication number Publication date
OA10546A (en) 2002-05-29
CA2224125C (en) 2004-09-28
HUP9801905A3 (en) 2001-04-28
EA001413B1 (ru) 2001-02-26
JP3238412B2 (ja) 2001-12-17
CZ380397A3 (cs) 1998-03-18
ES2182996T3 (es) 2003-03-16
DE69624354T2 (de) 2003-06-05
HUP9801905A2 (hu) 1999-05-28
CZ292192B6 (cs) 2003-08-13
SK282121B6 (sk) 2001-11-06
EP0831826A1 (en) 1998-04-01
PL184820B1 (pl) 2002-12-31
MX9709193A (es) 1998-03-31
ATE226075T1 (de) 2002-11-15
IS2661B (is) 2010-08-15
SK162797A3 (en) 1998-05-06
NO975665L (no) 1998-02-05
HK1010136A1 (en) 1999-06-17
DK0831826T3 (da) 2003-02-03
CA2224125A1 (en) 1996-12-12
PL323860A1 (en) 1998-04-27
NO324531B1 (no) 2007-11-12
AU6300496A (en) 1996-12-24
IL122353A0 (en) 1998-04-05
HU223899B1 (hu) 2005-03-29
PT831826E (pt) 2003-02-28
BG102106A (en) 1998-08-31
DE69624354D1 (de) 2002-11-21
JPH10507202A (ja) 1998-07-14
CN1186434A (zh) 1998-07-01
NZ311646A (en) 2000-02-28
EA199800023A1 (ru) 1998-08-27
CN1092960C (zh) 2002-10-23
CY2373B1 (en) 2004-06-04
IS4627A (is) 1997-12-04
BR9610842A (pt) 1999-07-13
AU709796B2 (en) 1999-09-09
EP0831826B1 (en) 2002-10-16
BG63711B1 (bg) 2002-10-31
WO1996039142A1 (en) 1996-12-12
TR199701541T1 (xx) 1998-03-21

Similar Documents

Publication Publication Date Title
NO975665D0 (no) Farmasöytisk sammensetning inneholdende en proteinaseinhibitor og et monoglyserid
NO982809L (no) Prolegemidler av tombin-inhibitorer
PL323710A1 (en) Reversible inhibitors of cysteinic protease
MY116525A (en) Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
HUP9901410A3 (en) Nitrile derivatives as inhibitors of tumor necrosis factor alpha and pharmaceutical compositions containing them
NO962269D0 (no) Enzyminhibitorer
IL135377A0 (en) Pharmaceutical compositions comprising mtp inhibitors
ATE218336T1 (de) Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
EP0671944A4 (en) TISSUE VIA-THROMBOPLASTIN FACTOR COMPLEX INHIBITORS DERIVED FROM A BOVINE PANCREATIC TRYPSIN INHIBITOR.
HRP20030983B1 (en) Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester
IL117247A (en) Pharmaceutical compositions comprising protease inhibitors and quinoxalines
NZ502133A (en) Method of enhancing bioavailability of fexofenadine and its derivatives
IL122942A0 (en) Esters of 1-beta-d-arabinofuranosylcytosine and pharmaceutical compositions containing them
NO308004B1 (no) Nye aminofenylfosfonsyreforbindelser og farmasøytiske sammensetninger inneholdende dem
ZA968444B (en) Methods of inhibiting plasminogen activator inhibitor 1.
ECSP961778A (es) Composiciones que incrementan la biodisponibilidad de inhibidores de proteinasa
ZA93857B (en) Novel aminoacetylmercapto derivatives useful as inhibitors of enkephalinase and ACE.
ZA969078B (en) Inhibitors of cysteine protease.
TNSN96081A1 (fr) Composition antiretrovirale
NO895071D0 (no) Plasmid for ekspresjon av alfa2-plasmidinhibitor.

Legal Events

Date Code Title Description
MK1K Patent expired